Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02577718
Other study ID # NiCE
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received October 13, 2015
Last updated October 2, 2017
Start date November 2015
Est. completion date October 2016

Study information

Verified date October 2017
Source Novel Anti-Infective Technologies, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this Phase I/II pilot study is to evaluate the safety and effectiveness of a non- antibiotic chelator based lock solution that contains nitroglycerin in combination with sodium citrate and ethanol (NiCE lock solution) for prevention of central line associated bloodstream infection (CLABSI).

- The primary objective of this study is to evaluate the safety and estimate the rate of adverse events associated with the NiCE lock solution.

- The second primary objective is to estimate the rate of CLABSI in patients receiving the NiCE lock solution.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date October 2016
Est. primary completion date June 22, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Inpatients who have a long term central venous catheter (CVC)—and the CVC has been in place for at least 14 days and is expected to remain in place at least for 30 days after enrollment

- The CVC consists of a 5.0 French size, dual-lumen, peripherally inserted central catheter

- Patients who are willing and capable to provide Informed Consent

- Patients who are willing and capable to follow the instructions required to complete the study

- Females (of child bearing potential) and males (of child bearing potential) must be abstinent or agree to use birth control during the study.

Exclusion Criteria:

- Patients who have an antimicrobial CVC.

- Patients who have a short term CVC that have been placed in ICU (mainly rigid wall CVCs placed for acute care in ICU).

- Patients who are hypotensive with a systolic blood pressure reading of <110 mmHg at any time over the 3 days prior to study entry

- Patients who are not awake, not alert, or who cannot express pain or discomfort related to the catheter locks

- Patients with an existing local or systemic infection as defined by evidence of fever (a body temperature > 38.0o C with two readings taken at least 10 minutes apart or one body temperature > 38.3o) and any of the following within 24 hours of enrollment: Pulse rate > 100 beats/min.; Respiratory rate > 20/min.; WBC count >12,000/mm3, <4,000/mm3 or differential count showing >10% band forms. Patient will still be eligible for the study if the participant's white blood cell count (WBC) is outside normal limits due to chemotherapy treatment or underlying conditions. Systolic blood pressure <90 mm Hg.

- Signs and symptoms of localized catheter-related infection (tenderness and/or pain, erythema, swelling, purulent exudates within 2 cm of entry site)

- Patients with an occluded (partially or totally) catheter defined as inability to either withdraw blood or instill 3cc of fluid without resistance through any catheter lumen

- Patients with multiple co-existing central venous catheters at the time of enrollment will not be enrolled.

- Patients in whom the lock solution application will interfere with routine treatment of the underlying disease

- Patients with a known history of allergic reaction to ethanol, nitroglycerin, or citrate.

- Female patients who are pregnant or breast feeding

- Patients who are on disulfiram, metronidazole or are dependent on alcohol

- Patients receiving phosphodiesterase type 5 (PDE-5) inhibitors (such as sildenafil, tadalafil, vardenafil).

Study Design


Intervention

Drug:
Nitroglycerin-citrate-ethanol (NiCE)
Lock solution instilled in catheter lumens for 2 hours then flushed. Administration for up to 30 days, daily as in-patient or once weekly as out-patient

Locations

Country Name City State
United States MD Anderson Cancer Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
Novel Anti-Infective Technologies, LLC M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

References & Publications (1)

Chaftari AM, Hachem R, Szvalb A, Taremi M, Granwehr B, Viola GM, Sapna A, Assaf A, Numan Y, Shah P, Gasitashvili K, Natividad E, Jiang Y, Slack R, Reitzel R, Rosenblatt J, Mouhayar E, Raad I. A Novel Nonantibiotic Nitroglycerin-Based Catheter Lock Solutio — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Drug-Related Hypotension Drug-related hypotension is defined as a significant drop in measured blood pressure (BP) that exceeds the normal BP variability of a patient by 30%, that is associated with clinical signs and symptoms (dizziness and syncope) and is unexplained by factors other than the lock solution (such as other antihypertensive drugs, sepsis, bleeding). BP variability will be based on the standard deviation (SD) of a patient's blood pressure measured in the 3 days preceding participation in this trial and will be calculated at the time of trial entry. From date of randomization until date of first Drug-Related Hypotension within 10 minutes of each flush, assessed up to 60 days
Secondary Incidence of Catheter-Associated Infections Catheter-Associated Infections will be measured by microbiological culture defined as either Catheter-Related Bloodstream Infection (CRBSI) as defined by the Infectious Diseases Society of America (IDSA), particularly in neutropenic patients, or Central Line-Associated Bloodstream Infection (CLABSI) as defined by the Centers for Disease Control and Prevention (CDC), particularly in non-neutropenic patients 60 Days
See also
  Status Clinical Trial Phase
Terminated NCT04787926 - DuraLock-C Catheter Lock Solution
Active, not recruiting NCT02515201 - Heparin Versus Taurolidine to Bloodstream Infection Prevention Related in Central Venous Catheter in Children Phase 4
Recruiting NCT04140916 - Comparison of Two Peripheral Inserted Intravenous Catheters N/A
Not yet recruiting NCT06019897 - Impact of Tubing Colonization on the Incidence of Central Venous Catheter Infection
Completed NCT02970409 - Heparin Versus Saline in Peripheral Venous Catheter N/A
Completed NCT03101371 - Reducing Urinary Tract Infection Rates Using a Controlled Aseptic Protocol for Catheter Insertion Phase 2
Completed NCT04821193 - Comparison of the Effects of 5%NaHCO3, 2%CHG and 70%Alcohol in the Prevention of Infections Related to Catheter N/A
Completed NCT04155723 - Impact of a Task Delegation to ICU Nurses for Midlines' Placement
Completed NCT02279121 - ATAPAC Study (TauroLock Activity in Adult Cancer Patients) N/A
Completed NCT00965198 - Comparison of Infection Rates Among Patients Using Two Catheter Access Devices N/A
Recruiting NCT05741866 - Novel Antimicrobial Dressing in Peripheral Intravenous Catheters (PIVCs) N/A
Recruiting NCT04825314 - Noble Meta Alloy Coated Catheters in Patients With Long Term Catheterization N/A
Active, not recruiting NCT03945045 - A Study of the IJV or the SCV Approach for Ultrasound-guided Implantation of TIVAD N/A
Active, not recruiting NCT01592032 - Concentration of Antimicrobials in Catheter-lock Solutions Phase 4
Terminated NCT04906512 - Comparing CHG I.V. Securement Dressing With Transparent Dressing for Evaluation of Antimicrobial Efficacy N/A
Withdrawn NCT02899780 - Treatment of Infected Dialysis Catheters With Fiber Optic Ultraviolet Light N/A
Recruiting NCT05995080 - The Effectiveness of Chlorhexidine Gluconate on Prevention of Catheter-Related Bloodstream Infections N/A
Completed NCT04794231 - Comparison of Chlorhexidine Impregnated Dressing and Standard Dressing N/A
Terminated NCT03447639 - Betadine Bladder Irrigations vs. Standard of Care Prior to Indwelling Catheter Removal Phase 4
Completed NCT03950921 - Pilot Testing a Patient Safety Display in the Hospital Setting N/A